ArticleMolecular and cellular biology1996
The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor.
Article in Molecular and cellular biology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 78 citations in OpenAlex.
- Elf1 Deficiency Impairs Macrophage Development in Zebrafish Model Organism.International journal of molecular sciences · 2025Article
- TheCirculation research · 2022Article
- A frameshift variant in specificity protein 1 triggers superactivation of Sp1-mediated transcription in familial bone marrow failure.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- E2A Antagonizes PU.1 Activity through Inhibition of DNA Binding.BioMed research international · 2016Article
- Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis.Leukemia · 2010Review
- Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.Genes, chromosomes & cancer · 2009Article
- The transcriptional repressor GFI-1 antagonizes PU.1 activity through protein-protein interaction.The Journal of biological chemistry · 2007Article
- Article
- Characterization of a novel, cytokine-inducible carboxypeptidase D isoform in haematopoietic tumour cells.The Biochemical journal · 2005Article
- Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat.Oncogene · 2003Article
- Macrophage-specific gene expression: current paradigms and future challenges.International journal of hematology · 2002Review
- Review
- Activated Fes protein tyrosine kinase induces terminal macrophage differentiation of myeloid progenitors (U937 cells) and activation of the transcription factor PU.1.Molecular and cellular biology · 2002Article
- FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow.The Journal of experimental medicine · 2001Article
- Ets target genes: past, present and future.Oncogene · 2000Review
- Review
- Expression pattern of the Ets-related transcription factor Elf-1.Molecular medicine (Cambridge, Mass.) · 1998Article
- Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B.The EMBO journal · 1997Article
- Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.Journal of virology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The protein product of the c-fps/fes (c-fes) proto-oncogene has been implicated in the normal development of myeloid cells (macrophages and neutrophils). mRNA for c-fes has been detected exclusively in myeloid cells and vascular endothelial cells in adult mammals. Although a 13-kilobase-pair (kb) human c-fes transgene exhibits high levels of expression in mice, the sequences that confer myeloid-cell-specific expression of the human c-fes gene have not been defined. Transient-transfection experiments demonstrated that plasmids containing 446 bp of c-fes 5'-flanking sequences linked to a luciferase reporter gene were active exclusively in myeloid cells. No other DNA element within the 13-kb human c-fes locus contained positive cis-acting elements, with the exception of a weakly active region within the 3'-flanking sequences. DNase I footprinting assays revealed four distinct sites that bind myeloid nuclear proteins (-408 to -386, -293 to -254, -76 to -65, and -34 to +3). However, the first two footprints resided in sequences that were largely dispensable for transient activity. Plasmids containing 151 bp of 5'-flanking sequences confer myeloid-cell-specific gene expression. Electrophoretic mobility shift analyses demonstrated that the 151-bp region contains nuclear protein binding sites for Sp1, PU.1, and/or Elf-1, and a novel factor. This unidentified factor binds immediately 3' of the PU.1/Elf-1 sites and appears to be myeloid cell specific. Mutation of the PU.1/Elf-1 site or the 3' site (FP4-3') within the context of the c-fes promoter resulted in substantially reduced activity in transient transfections. Furthermore, transient-cotransfection assay demonstrated that PU.1 (and not Elf-1) can transactivate the c-fes promoter in nonmyeloid cell lines. We conclude that the human c-fes gene contains a strong myeloid-cell-specific promoter that is regulated by Sp1, PU.1, and a novel transcription factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.